Mendus has partnered with Australia’s SAHMRI for its upcoming Phase IIa VITAL-TFR2 trial, targeting Chronic Myeloid Leukemia patients attempting a second treatment-free remission. By deploying the vididencel immunotherapy against a group facing a steep 70% standard relapse rate, this collaboration offers a highly efficient way to prove clinical efficacy without a massive placebo-controlled study.
LÄS MER
